AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02038894
Drug: Intubated with Sevoflurane (IS)
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
Trial: NCT02038894
Drug: Intubated with Propofol (IP)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
Trial: NCT02038894
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01939509
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
Trial: NCT01939509
Drug: Bisoprolol
RxNorm normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03673618
Drug: Soluble Corn Fiber
RxNorm normalized name: soluble corn fiber
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiber or placebo
Trial: NCT01708278
Drug: Quercetin
RxNorm normalized name: Quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~1. Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~2. Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~3. Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin
Trial: NCT03742115
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
Trial: NCT03742115
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m2 weekly
Trial: NCT03742115
Drug: IVIG
RxNorm normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg, once every 4 weeks
Trial: NCT02729805
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10ml bolus injection of saline followed by intravenous infusion of saline during the operation
Trial: NCT02729805
Drug: Ketamine 0.5mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
Trial: NCT02729805
Drug: Ketamine 0.75mg/kg
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
Trial: NCT00627848
Drug: rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
Trial: NCT00276692
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01722942
Drug: amiodarone hydrochloride
RxNorm normalized name: Amiodarone Hydrochloride
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amiodarone prescription
Trial: NCT00045305
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressant
Trial: NCT00045305
Drug: Mycofenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: an antibiotic with immunosuppressamt properties isolated from Penicillium spp
Trial: NCT00045305
Drug: Pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Purine analogue
Trial: NCT01122914
Drug: Anakinra
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03693807
Drug: Floxuridine (FUDR)
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Please see Detailed Description.
Trial: NCT03693807
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Please see Detailed Description.
Trial: NCT03693807
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Please see Detailed Description.
Trial: NCT03693807
Drug: Irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Please see Detailed Description.
Trial: NCT00622700
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet Oral administration
Trial: NCT00953355
Drug: Folate plus metformin
RxNorm normalized name: folate
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
Trial: NCT00953355
Drug: Placebo plus metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A six-month course of metformin (1700 mg daily) plus placebo
Trial: NCT01602185
Drug: Dextromethorphan (drug used like antitussive)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Trial: NCT01602185
Drug: Memantine (drug used in Alzheimer's disease)
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PARKINSON'S DISEASE
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
Trial: NCT02170532
Drug: levalbuterol
RxNorm normalized name: Levalbuterol
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 ml. levalbuterol
Trial: NCT02170532
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5ml saline
Trial: NCT02170532
Drug: ipratroprium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00942266
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02644122
Drug: SF1126
RxNorm normalized name: SF1126
DrugBank: SF1126 (DB05210)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00162253
Drug: BMS 587101
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03611556
Drug: Oleclumab
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV infusion of oleclumab as stated in arm description.
Trial: NCT03611556
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Trial: NCT03611556
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.
Trial: NCT00005810
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005810
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005810
Drug: estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00986076
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
Trial: NCT00986076
Drug: Balanced Salt Solution
RxNorm normalized name: Balanced Salt Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraocular infusion of Balanced Salt solution
Trial: NCT00050180
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00050180
Drug: Indinavir
RxNorm normalized name: Indinavir
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00050180
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01962870
Drug: Vasopressin
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
Trial: NCT01154881
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
Trial: NCT00210379
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00210379
Drug: CHOP
RxNorm normalized name: cinchophen
DrugBank: Trichophyton mentagrophytes (DB10446)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00034203
Drug: efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00227617
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
Trial: NCT00227617
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200mg/m2 IV q 2 wk on day 1 over a 2-hour period
Trial: NCT02259738
Drug: Human Urinary Kallidinogenase
RxNorm normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03943784
Drug: Non-Selective Beta-Blocking Agent
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
Trial: NCT04370925
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy regimens: CapeOx and mFOLFOX6 are preferred for stage Ⅲ patients.~CapeOx:oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~mFOLFOX6:oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~For stageⅡpatiens, regimens recommend by NCCN guide line(2019 v1) are acceptable.
Trial: NCT04475432
Drug: TP-03 Vehicle
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vehicle of TP-03 ophthalmic solution, administered twice a day
Trial: NCT03611556
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
Trial: NCT03427684
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 80mg/m2/day, orally intake on radiotherapy days.
Trial: NCT03611556
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV infusion of oxaliplatin as stated in arm description.
Trial: NCT03611556
Drug: Folinic acid
RxNorm normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV infusion of folinic acid as stated in arm description.
Trial: NCT03611556
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive IV infusion of 5-FU as stated in arm description.
Trial: NCT05142449
Drug: Amoxilan
RxNorm normalized name: Ioxilan
DrugBank: Ioxilan (DB09135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive 8 capsules Amoxilan perioperatively and for the next 3 days 6 capsules per day
Trial: NCT01683084
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00457470
Drug: AG-014699
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00248378
Drug: Smoked Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02440633
Drug: 14C-OPS-2071
RxNorm normalized name: urea [14C]
DrugBank: Urea C-13 (DB09510)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
Trial: NCT00579280
Drug: divalproex sodium ER
RxNorm normalized name: Divalproex Sodium ER
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
Trial: NCT02397707
Drug: Voxilaprevir
RxNorm normalized name: Voxilaprevir
DrugBank: Voxilaprevir (DB12026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablet administered orally
Trial: NCT02157948
Drug: Denosumab (CP2)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
Trial: NCT01679561
Drug: intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
Trial: NCT02157948
Drug: Denosumab (CP4)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
Trial: NCT00142246
Drug: Intermittent preventive treatment (SP and amodiaquine)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
Trial: NCT00399685
Drug: Ortho Tri-Cyclen LO
RxNorm normalized name: Ortho Tri-Cyclen Lo
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
Trial: NCT00399685
Drug: Ortho Cyclen
RxNorm normalized name: Ortho Cyclen
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
Trial: NCT00399685
Drug: Ortho Cyclen + Efavirenz
RxNorm normalized name: norgestimate
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
Trial: NCT01634945
Drug: SP/amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
Trial: NCT01634945
Drug: SP/Amodiaquine + FeFum fortified porridge
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =\< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =\< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
Trial: NCT00399685
Drug: Ortho Cyclen
RxNorm normalized name: Ortho Cyclen
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
Trial: NCT01524497
Drug: Trazodone
RxNorm normalized name: Trazodone
DrugBank: Trazodone (DB00656)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg tablet/150 mg tablet
Trial: NCT01276275
Drug: Risk of selected safety events
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First time users of ticagrelor, clopidogrel and prasugrel, respectively
Trial: NCT02852824
Drug: BI 655130 (spesolimab)
RxNorm normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04780945
Drug: Olaparib Oral Product
RxNorm normalized name: olaparib Oral Product
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg bid
Trial: NCT00999336
Drug: Betrixaban
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg betrixaban qd for 8 days
Trial: NCT01012063
Drug: iron sucrose, erythropoietin-β
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
Trial: NCT00211549
Drug: IDEA-033
RxNorm normalized name: ALUMINUM ZIRCONIUM OCTACHLOROHYDREX GLY 16.4 g in 100 g TOPICAL GEL [Dry Idea Antiperspirant]
DrugBank: Aluminum zirconium octachlorohydrex gly (DB11200)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00406887
Drug: Difluprednate Ophthalmic Emulsion
RxNorm normalized name: Difluprednate Ophthalmic Emulsion
DrugBank: Difluprednate (DB06781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00968903
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 125 mg iv pre-operatively
Trial: NCT00881296
Drug: gemcitabine and carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
Trial: NCT00881296
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
Trial: NCT02101138
Drug: Dexpramipexole
RxNorm normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
Trial: NCT01706666
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT01706666
Drug: lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01706666
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00002544
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002544
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01263496
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
Trial: NCT01263496
Drug: Alogliptin
RxNorm normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.